Ratings Vieworks Co., Ltd.

Equities

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-07-02 pm EDT			5-day change	1st Jan Change
27,500 ^KRW	-1.61%		-3.51%	+1.85%

2023	Vieworks Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
2023	Vieworks' Vivix X-Ray Flat Panel Detector Full Line-Up to Be Showcased At Ecr 2023	CI

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
The company's attractive earnings multiples are brought to light by a P/E ratio at 10.13 for the current year.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
VIEWORKS CO., LTD.	+1.85%	185M		-
SHANGHAI UNITED IMAGING HEALTHCARE CO., LTD.	-23.43%	11.96B		-
SONOSCAPE MEDICAL CORP.	-24.33%	2.2B		-
IRAY TECHNOLOGY COMPANY LIMITED	-53.60%	2.16B		C-
BEIJING WANDONG MEDICAL TECHNOLOGY CO.,LTD.	-28.04%	1.2B	-	-
CORETAG, INC.	-.--%	1.12B	-	-
GUERBET	+85.38%	486M		B+
NANO-X IMAGING LTD.	+10.83%	396M		-
DETECTION TECHNOLOGY OYJ	+31.75%	293M		C
DRTECH CORPORATION	-12.56%	199M	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality